| Predicted Trait | |
| Reported Trait | Type 2 diabetes (T2D) |
| Mapped Trait(s) | type 2 diabetes mellitus (MONDO_0005148) |
| Score Construction | |
| PGS Name | GRSt |
| Development Method | |
| Name | Genome-wide significant variants |
| Parameters | Index SNPs or their proxies |
| Variants | |
| Original Genome Build | NCBI36 |
| Number of Variants | 62 |
| Effect Weight Type | NR |
| PGS Source | |
| PGS Catalog Publication (PGP) ID | PGP000020 |
| Citation (link to publication) | Vassy JL et al. Diabetes (2014) |
| Ancestry Distribution | |
| Source of Variant Associations (GWAS) | European: 100% 69,033 individuals (100%) |
| PGS Evaluation | European: 40% Greater Middle Eastern: 40% African: 20% 5 Sample Sets |
| Study Identifiers | Sample Numbers | Sample Ancestry | Cohort(s) |
|---|---|---|---|
GWAS Catalog: GCST005047 Europe PMC: 22885922 |
69,033 individuals | European | NR |
|
PGS Performance Metric ID (PPM) |
PGS Sample Set ID (PSS) |
Performance Source | Trait |
PGS Effect Sizes (per SD change) |
Classification Metrics | Other Metrics | Covariates Included in the Model |
PGS Performance: Other Relevant Information |
|---|---|---|---|---|---|---|---|---|
| PPM000062 | PSS000044| European Ancestry| 3,471 individuals |
PGP000020 | Vassy JL et al. Diabetes (2014) |
Reported Trait: Incident type 2 diabetes cases | HR: 1.06 [1.04, 1.08] | C-index: 0.906 [0.892, 0.92] | — | age, sex, family history (parents), body mass index, systolic blood pressure, fasting glucose, log-HDL cholesterol, log-triglyceride levels | Results from the "Clinical model" |
| PPM000063 | PSS000043| European Ancestry| 1,650 individuals |
PGP000020 | Vassy JL et al. Diabetes (2014) |
Reported Trait: Incident type 2 diabetes cases | HR: 1.06 [1.02, 1.1] | C-index: 0.853 [0.81, 0.896] | — | age, sex, family history (parents), body mass index, systolic blood pressure, fasting glucose, log-HDL cholesterol, log-triglyceride levels | Results from the "Clinical model" |
| PPM000064 | PSS000042| African Ancestry| 820 individuals |
PGP000020 | Vassy JL et al. Diabetes (2014) |
Reported Trait: Incident type 2 diabetes cases | HR: 1.05 [1.0, 1.09] | C-index: 0.771 [0.727, 0.814] | — | age, sex, family history (parents), body mass index, systolic blood pressure, fasting glucose, log-HDL cholesterol, log-triglyceride levels | Results from the "Clinical model", SNPs were not weighted by their effect size as the betas were measure in Europeans |
| PPM022773 | PSS012080| Greater Middle Eastern Ancestry| 4,534 individuals |
PGP000753 | Aliyu U et al. Diabetes Obes Metab (2025) |Ext. |
Reported Trait: Prediabetes | OR: 1.155 [1.086, 1.229] | AUROC: 0.647 [0.631, 0.662] | R²: 0.082 | sex, baseline age, BMI, PCs1-10 | — |
| PPM022916 | PSS012081| Greater Middle Eastern Ancestry| 2,143 individuals |
PGP000753 | Aliyu U et al. Diabetes Obes Metab (2025) |Ext. |
Reported Trait: Incident T2D in prediabetics | HR: 1.455 [1.266, 1.671] | AUROC: 0.77 [0.737, 0.803] | — | sex, baseline age, BMI, PCs1-10 | — |
|
PGS Sample Set ID (PSS) |
Phenotype Definitions and Methods | Participant Follow-up Time | Sample Numbers | Age of Study Participants | Sample Ancestry | Additional Ancestry Description | Cohort(s) | Additional Sample/Cohort Information |
|---|---|---|---|---|---|---|---|---|
| PSS012080 | age-matched cohort | — | [
|
— | Greater Middle Eastern (Middle Eastern, North African or Persian) (Qatari) |
— | QBB | — |
| PSS012081 | — | Median = 6.0 years | [ ,
54.22 % Male samples |
— | Greater Middle Eastern (Middle Eastern, North African or Persian) (Qatari) |
— | QBB | — |
| PSS000042 | T2D was defined by a fasting plasma glucose ≥7.0 mmol/L (≥126 mg/dL) or report of taking diabetes medications | — | [ ,
38.8 % Male samples |
— | African American or Afro-Caribbean | — | CARDIA | — |
| PSS000043 | T2D was defined by a fasting plasma glucose ≥7.0 mmol/L (≥126 mg/dL) or report of taking diabetes medications | — | [ ,
46.5 % Male samples |
— | European | — | CARDIA | — |
| PSS000044 | T2D was defined by a fasting plasma glucose ≥7.0 mmol/L (≥126 mg/dL) or report of taking diabetes medications | — | [ ,
46.6 % Male samples |
— | European | — | FOS | — |